Therapeutic strategies to prevent motor complications in Parkinson's disease.
作者： Karl Kieburtz
DOI: 10.1007/S00415-008-4007-4
关键词:
摘要: Dopaminergic treatment of Parkinson's disease (PD) leads to significant improvement in Parkinsonian features; however, the response is hampered by appearance motor complications, including dyskinesias and fluctuations. These complications have a negative impact on quality-of-life. Therapeutic strategies using different types timing dopaminergic therapy may influence emergence complications. While sustained release preparations levodopa not shown benefit over immediate preparations, early combination dopamine agonist with appears reduce onset An even larger body evidence has found that initiating receptor (as compared levodopa) associated reduction fluctuations, particularly dyskinesias. data led evidence-based medicine evaluations indicating use agonists efficacious clinically useful for prevention
springer.com
sci-hub.se 参考文章(16)
H. Przuntek, D. Welzel, M. Gerlach, E. Bl�mner, W. Danielczyk, H. -J. Kaiser, P. H. Kraus, H. Letzel, P. Riederer, K. �berla, Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study. Journal of Neural Transmission. ,vol. 103, pp. 699- 715 ,(1996) , 10.1007/BF01271230
Stéphane Chapuis, Lemlih Ouchchane, Olivier Metz, Laurent Gerbaud, Franck Durif, Impact of the motor complications of Parkinson's disease on the quality of life. Movement Disorders. ,vol. 20, pp. 224- 230 ,(2005) , 10.1002/MDS.20279
Christopher G Goetz, Werner Poewe, Olivier Rascol, Cristina Sampaio, None, Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Movement Disorders. ,vol. 20, pp. 523- 539 ,(2005) , 10.1002/MDS.20464
Wolfgang H. Oertel, Erik Wolters, Cristina Sampaio, Santiago Gimenez-Roldan, Bruno Bergamasco, Max Dujardin, Donald G. Grosset, Guy Arnold, Klaus L. Leenders, Hans-Peter Hundemer, Alberto Lledó, Andrew Wood, Paul Frewer, Johannes Schwarz, Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study Movement Disorders. ,vol. 21, pp. 343- 353 ,(2006) , 10.1002/MDS.20724
Olivier Rascol, David J Brooks, Amos D Korczyn, Peter P De Deyn, Carl E Clarke, Anthony E Lang, None, A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa The New England Journal of Medicine. ,vol. 342, pp. 1484- 1491 ,(2000) , 10.1056/NEJM200005183422004
R. Kurlan, D. Standaert, C. Casaceli, I. Shoulson, J. Seibyl, D. Amyot, R. Holloway, R. Rodnitzky, P. Tariot, J. Jankovic, L. Barclay, M. Harrigan, T. Shirley, I. Gardiner, S. Rast, A. Rajput, P. Rainey, K. Marek, A. Lang, A. Watts, S. Schuman, M. McDermott, A. Brocht, C. Kamp, B. Fussell, C. Weeks, C. O'Connell, L. Sutherland, M. Kurth, S. Daigneault, D. Day, K. Honsinger, K. Hildebrand, A. Shinaman, M. Brewer, S. Coe, R. Pahwa, S. Dillon, K. Hodgeman, E. Sime, D. Fontaine, M. Welsh, B. Ford, B. Pfeiffer, J. Dobson, D. Brown, S. Factor, J. Duff, C. Shults, C. Waters, F. Atassi, J. Hammerstad, M. Panisset, J. Hall, J. Hubble, E. Rost-ruffner, P. Lewitt, M. Tennis, F. Wooten, D. S. Russell, W. Weiner, D. Riley, R. Pfeiffer, O. Suchowersky, C. Stone, J. Miyasaki, M. Stacy, K. Kieburtz, S. Fahn, Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial JAMA. ,vol. 284, pp. 1931- 1938 ,(2000)
W. C. Koller, J. T. Hutton, E. Tolosa, R. Capilldeo, Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology. ,vol. 53, pp. 1012- 1019 ,(1999) , 10.1212/WNL.53.5.1012
Takao Nakanishi, Makoto Iwata, Ikuo Goto, Ichiro Kanazawa, Hisayuki Kowa, Tohru Mannen, Yoshikuni Mizuno, Hiroshi Nishitani, Norio Ogawa, Akira Takahashi, Kunio Tashiroi, Hideo Tohgi, Nobuo Yanagisawa, Nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of Parkinsonian patients : final report European Neurology. ,vol. 32, pp. 9- 22 ,(1992) , 10.1159/000116865
E. Dupont, A. Andersen, J. Boas, E. Boisen, R. Borgmann, A. C. Helgetveit, M. O. Kjaer, T. N. Kristensen, B. Mikkelseng, H. Pakkenberg, J. Presthus, R. Stien, J. Worm-Petersen, D. Buch, Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurologica Scandinavica. ,vol. 93, pp. 14- 20 ,(2009) , 10.1111/J.1600-0404.1996.TB00163.X
H. Allain, A. Destée, H. Petit, M. Patay, S. Schück, D. Bentué-Ferrer, P. Le Cavorzin, Five-Year Follow-Up of Early Lisuride and Levodopa Combination Therapy versus Levodopa Monotherapy in de novo Parkinson’s Disease European Neurology. ,vol. 44, pp. 22- 30 ,(2000) , 10.1159/000008188